阿帕替尼治疗恶性肿瘤致继发性高血压的危险因素分析

Risk Factors of Secondary Hypertension Induced by Malignant Tumors Treated with Apatinib

目的:分析阿帕替尼治疗恶性肿瘤致继发性高血压的危险因素。方法:收集2016年5月至2018年3月接受阿帕替尼治疗的恶性肿瘤患者60例,包括患者一般情况,如性别、年龄、BMI、肿瘤类型、病理类型、ECOG评分、放疗史、化疗史、手术史、吸烟史、药物剂量及既往病史,采用单因素分析和Logistic回归分析评估发生高血压的危险因素。结果:60例患者中,共21例发生高血压,其中Ⅰ级9例,占42.86%,Ⅱ级6例,占28.57%,Ⅲ级6例,占28.57%,无高血压危象发生,经药物控制后稳定率100%。单因素分析,发现年龄、BMI、ECOG评分、吸烟史和药物剂量与阿帕替尼致继发性高血压有关(P<0.05),而性别、肿瘤类型、病理类型、放疗史、化疗史及手术史不影响患者治疗过程中高血压的发生(P>0.05)。将单因素分析中有统计学意义的自变量进行多因素Logistic回归分析,得出年龄(OR=4.310,95%CI=3.097～5.813)是阿帕替尼致继发性高血压的独立危险因素(P<0.05)。结论:年龄是阿帕替尼治疗恶性肿瘤致继发性高血压的危险因素。

Objective To study the risk factors of secondary hypertension induced by malignant tumors treated with apatinib.Methods A total of 60 patients with malignant tumors treated with apatinib were collected from May 2016 to March 2018.The observed general conditions include gender,age,BMI,tumor type,pathological type,ECOG score,radiotherapy history,chemotherapy history,operation history,smoking history,drug dosage and past medical history.The risk factor for the occurrence of hypertension was evaluated using univariate analysis and Logistic regression analysis.Results Among the 60 patients,21 patients developed hypertension,including 9 cases of gradeⅠ,accounting for 42.86%,6 cases of gradeⅡ,accounting for 28.57%,and 6 cases of gradeⅢ,accounting for 28.57%.There was no hypertension crisis,and the stability rate was 100%after drug control.Univariate analysis showed that age,BMI,ECOG score,smoking history and drug dosage were associated with secondary hypertension induced by apatinib(P<0.05),while gender,tumor type,pathological type,radiotherapy history,chemotherapy history and operation history did not affect the occurrence of hypertension during treatment(P>0.05).Logistic regression analysis showed that age(OR=4.310,95%CI=3.097~5.813)was an independent risk factor for secondary hypertension induced by apatinib(P<0.05).Conclusion Age is a risk factor for secondary hypertension in patients with malignant tumors treated with apatinib.